(Q37128651)

18 August 2017

1 reference

title

Emerging evidence of the impact of kidney disease on drug metabolism and transport (English)

1 reference

18 August 2017

1 reference

1 reference

T D Nolin

1

1 reference

18 August 2017

J Naud

series ordinal

2

1 reference

18 August 2017

F A Leblond

series ordinal

3

1 reference

18 August 2017

V Pichette

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

2 April 2008

1 reference

Clinical Pharmacology & Therapeutics

18 August 2017

published in

1 reference

18 August 2017

volume

83

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

898-903

1 reference

Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

Pharmacokinetics of lomefloxacin in renally compromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

Disposition of roxithromycin in patients with normal and severely impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

Prevalence of chronic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

The biotransformation of drugs in renal failure

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Downregulation of intestinal cytochrome p450 in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effects of chronic renal failure on liver drug transporters

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Down-regulation of intestinal drug transporters in chronic renal failure in rats.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effects of uptake and efflux transporter inhibition on erythromycin breath test results

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effect of chronic renal insufficiency on hepatic and renal udp-glucuronyltransferases in rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Hepatic drug metabolism and transport in patients with kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effects of renal failure on drug transport and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Pharmacokinetics of repaglinide in subjects with renal impairment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Cytochrome P4502C9 activity in end‐stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Hemodialysis acutely improves hepatic CYP3A4 metabolic activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effects of uremic toxins on hepatic uptake and metabolism of erythromycin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effect of experimental renal failure on the pharmacokinetics of losartan in rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Grapefruit juice, a glass full of drug interactions?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Single-dose pharmacokinetics of felbamate in patients with renal dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Raloxifene pharmacokinetics in males with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.59

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.59

1 reference

18 August 2017

1 reference